ABOUT
R&D
PRODUCT
MANUFACTURING
NEWS
CLINICAL TRIALS
About US
R&D
Product
Manufacturing

Search: “Best Essay Writing Service 🎓www.WriteMyPaper.online 🎓Write Essay Cheap - Write Essay Fast”

We could not find any results for your search. You can give it another try through the search form below.

Recent Posts

  • New Technologies for Accessible, Durable and Broadly Protective Coronavirus Vaccines
  • IDRI to present at the Life Science Innovation Northwest Conference
  • Seattle’s Infectious Disease Research Institute Receives Federal Grant for Innovation to Enhance RNA Vaccine Efficacy
  • Three vaccines. Increased manufacturing. How US will have enough COVID-19 vaccine for every US adult in May – or even sooner.
  • Do Covid-19 vaccines work against new variants? Scientists explain.

Recent Comments

    Archives

    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    PHONE:
    FAX:
    EMAIL:
    206.381.0883
    206.381.3678
    office@idri.org
    1616 Eastlake Avenue East
    Suite 400
    Seattle, Washington 98102
    About
    R&D
    Product
    Manufacturing
    News
    Careers
    -
    Privacy Policy
    Conflict of Interest

    IDRI is a 501(c)(3) Washington non profit.

    On January 2, 2020, IDRI was placed into a voluntary receivership under the supervision of the King County Superior Court for the state of Washington. The receivership was in response to longstanding financial and management deficiencies, and the receiver replaced the board of directors. The Receiver, Shelly Crocker LLC, operates as a fiduciary to IDRI’s creditors and stakeholders, and is continuing to operate IDRI as a going concern. IDRI retains its corporate form and 501(c)(3) status, and will exit receivership upon completing its restructuring and repaying its creditors. The Receiver can be reached at shelly.crocker@idri.org, or through counsel Jennifer Faubion at Cairncross & Hemplemann.
    © 1993-2020 Infectious Disease Research Institute
    IDRI Privacy Policy
    IDRI respects the privacy of our online visitors. IDRI only collects personal information when website visitors choose to share information with us by signing up to receive newsletters or attend an event, making charitable contributions or applying for jobs. Any information IDRI collects will be used only for our internal purposes and will be maintained on a confidential basis. IDRI does not share or sell personal user information or contact lists with third parties. Notwithstanding other provisions of this privacy policy, IDRI may disclose any information collected through IDRI’s website when we believe in our sole discretion that such disclosure is necessary to comply with the law. This privacy policy applies only to information collected through our website. Other websites, including those that we may link to, may be governed by other policies.
    Conflict of Interest

    Federal Award Conflict of Interest Disclosure Policy

    As an organization that applies for and/or receives Public Health Service (PHS) funding, IDRI has established a Financial Conflict of Interest Policy. IDRI will make certain information regarding financial conflicts of interest of senior/key personnel on PHS-funded research projects available upon written request.

    Requests for information regarding such financial conflicts of interest may be made by sending an email with “Financial Conflict of Interest Request” in the subject line to office@idri.org or by mail to the following address:

    Infectious Disease Research Institute
    Attn: Financial Conflict of Interest Request
    1616 Eastlake Avenue East, Suite 400
    Seattle, WA 98102

    IDRI will respond within five business days of receipt of a written request.

    Information that will be made available is:

    • The Investigator’s name
    • The Investigator’s title and role with respect to the research project and the name of the entity in which the significant financial interest is held
    • The nature of the significant financial interest
    • The approximate dollar value of the significant financial interest, or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value
    • IDRI will note in its written response that the information provided is current as of the date of the correspondence and is subject to updates, on at least an annual basis and within 60 days of the Institution’s identification of a new financial conflict of interest, which should be requested subsequently by the requestor